tirzepatide ckd trial Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT Interplay of Chronic Kidney Disease

doi: 10.1007/s001250100006 52 ChengCJabriSTaokaBMSinzCJ

Key Research Characteristics: Selective NNMT inhibition, supporting studies into NAD metabolism and methylation pathways Investigated in the context of obesity, metabolic dysfunction, and lipid accumulation models Cell-permeable small molecule with favourable in vitro profile Studied for potential effects on adipocyte differentiation and energy expenditure Specifications: Form: Lyophilised powder For research purposes only

Novo is "pleased" with the 23% weight loss that CagriSema caused, which shows that it offers "clinically meaningful additive weight loss effects" that are superior to what's been seen with drugs that only target GLP-1, Chief Scientific Officer Martin Holst Lange said in a release on Monday

However, the exact mechanism is not fully understood

ROS may be another potential stress metabolite affecting translocation, as N-acetylcysteine treatment inhibits oxidant-induced nuclear translocation [33, 39]